Impaired Capacity to Lose Visceral Adipose Tissue During Weight Reduction in Obese Postmenopausal Women With the Trp64Arg 3-Adrenoceptor Gene Variant André Tchernof, Raymond D. Starling, Amy Turner, Alan R. Shuldiner, Jeremy D. Walston, Kristi Silver, and Eric T. Poehlman
Controversy exists regarding the association between the Trp64Arg variant of the 3-adrenoceptor gene and visceral obesity. The cross-sectional nature of most studies, the modest effect of the variant, and sex or ethnic differences between groups have contributed to discrepancies among investigations. To overcome these confounding factors, we examined the effect of the Trp64Arg variant on total and visceral adipose tissue loss, insulin sensitivity, and cardiovascular disease risk factors in response to weight reduction in obese older women. A total of 24 women (age 57 ± 4 years), including 1 Trp64Arg homozygote, 10 Trp64Arg heterozygotes, and 13 normal homozygotes, were admitted to a weight reduction program of 13 ± 3 months, with weight and nutritional intake stabilization established before testing. Total and regional adiposity were measured with dual-energy X-ray absorptiometry and computed tomography, insulin sensitivity was measured by the hyperinsulinemic-euglycemic clamp technique, and a blood lipid profile was obtained. No baseline differences were noted in adiposity measurements, glucose disposal, and lipid profiles among carriers and noncarriers of the variant allele. In response to weight loss, carriers and noncarriers of the Trp64Arg allele had similar reductions in body weight (–16.4 ± 5.0 vs. –14.1 ± 6.2 kg, NS) and body fat (–10.0 ± 5.2 vs. –11.5 ± 3.9 kg, NS). However, loss of visceral adipose tissue was 43% lower in carriers of the Trp64Arg allele compared with noncarriers (–46 ± 27 vs. –81 ± 51 cm2, P = 0.05). Furthermore, there was less improvement in the total cholesterol–to–HDL cholesterol ratio (–0.18 ± 0.54 vs. –0.72 ± 0.56, P = 0.04) in carriers compared with noncarriers of the allele. Although glucose disposal improved in both groups, there was no difference in the magnitude of improvement between carriers and noncarriers of the variant allele. In conclusion, older obese women carrying the Trp64Arg 3-adrenoceptor From the Department of Medicine (A.Tc., R.D.S., A.Tu., E.T.P.), College of Medicine, University of Vermont, Burlington, Vermont; the Department of Medicine (A.R.S., K.S.), the Division of Endocrinology, Diabetes and Nutrition, University of Maryland, and the Geriatric Research Education and Clinical Center, Baltimore Veterans Administration Medical Center; and the Division of Geriatric Medicine and Gerontology (J.D.W.), Johns Hopkins University, Baltimore, Maryland. Address correspondence and reprint requests to Eric T. Poehlman, PhD, Department of Medicine, University of Vermont, Given Bldg. C-247, Burlington, VT 05405. E-mail:
[email protected]. Received for publication 27 December 1999 and accepted in revised form 27 June 1999. EGP, endogenous glucose production; TGD, total glucose disposal. DIABETES, VOL. 49, OCTOBER 2000
gene variant have an impaired capacity to lose visceral adipose tissue in response to prolonged caloric restriction. Despite these genetic differences in loss of intraabdominal adipose tissue, improvement in glucose disposal was similar between groups. Diabetes 49:1709– 1713, 2000
T
he variant of the 3-adrenergic receptor gene coding for the replacement of tryptophan by arginine at codon 64 (Trp64Arg) has been associated with increased visceral adipose tissue accumulation and related comorbidities in several studies (1–6). These results, however, are unclear because other investigators have found no effect of the polymorphism on this phenotype (7–11). Although the phenotypic expression of the Trp64Arg variant remains unclear at present, Lönnqvist et al. (12) demonstrated that 3-adrenoceptor–mediated lipolysis was partly responsible for the increased free fatty acid release from the intra-abdominal adipose tissue depot in humans. More recently, several studies have investigated the possibility of an impaired 3-adrenoceptor–mediated lipolysis in omental fat from subjects with the Trp64Arg variant (13–15). Experiments performed with a selective 3-adrenoceptor agonist (14,16) suggest that the Trp64Arg variant is associated with impaired lipolysis in adipose tissue from the intra-abdominal cavity. Discrepant results found among previous studies of the Trp64Arg variant of the 3-adrenoceptor gene and phenotypes of the insulin resistance syndrome may have been due to random sampling variations or cohort differences in ethnicity, sex, age, or degree of obesity. Discordant results may also be due to the cross-sectional nature of most investigations. Intervention studies provide a more rigorous approach to understanding the effects of this genetic variant, especially in obese populations. We have recently suggested that the obese state may mask moderate effects of this variant (11). Thus, we undertook a study in which obese women underwent weight reduction in an attempt to clarify possible effects of the 3-adrenoceptor gene variant on the ability to respond to weight loss. We tested the hypothesis that obese postmenopausal women with the Trp64Arg variant have an impaired capacity to lose intra-abdominal adipose tissue in response to a weight 1709
VISCERAL FAT LOSS AND THE Trp64Arg VARIANT
reduction intervention compared with normal homozygotes. We studied 24 obese postmenopausal women (with and without the Trp64Arg variant) that underwent a 13-month weight reduction program, which included weight and nutritional intake stabilization before testing. RESEARCH DESIGN AND METHODS Subjects. Postmenopausal obese Caucasian women in the greater Burlington, Vermont, area were recruited by local advertisement. A total of 491 obese women were screened, of which 38 were heterozygotes for the Trp64Arg variant (allele frequency 0.10). Of this initial cohort, 24 obese women (1 Arg64Arg homozygote, 10 Trp64Arg heterozygotes, and 13 normal homozygotes) completed the weight loss program. Inclusion criteria were the cessation of menstruation for at least 1 year, a BMI >27 kg/m2, and physical inactivity. Women also had to be nonsmokers and nondiabetic. Other exclusion criteria included atherosclerosis, hypertension (diastolic blood pressure >90 mmHg), orthopedic limitations or history of fractures, weight loss/gain over the previous 6 months, or thyroid or pituitary disease. Screening for the presence of the Trp64Arg variant was performed after subjects gave their informed consent. This study was approved by the Committee on Human Research and Medical Sciences of the University of Vermont. Genotyping. Genotyping for the Trp64Arg variant in the 3-adrenoceptor gene was performed as previously described (17) by polymerase chain reaction–restriction fragment-length polymorphism analysis. Weight loss protocol. There were 24 women who entered a medically supervised weight loss program aimed at reducing body weight to 130 cm2 is likely to be found in combination with several alterations in the metabolic profile (28). Thus, it is likely that the rather moderate improvements in lipid profile and our inability to detect genotype effects is attributable to the persistent elevated intra-abdominal fat areas, even after weight loss. In summary, we found that older obese women carrying the Trp64Arg 3-adrenoceptor gene variant have an impaired capacity to lose visceral adipose tissue in response to prolonged caloric restriction. This phenotypic trait may be attributable to an impaired 3-adrenoceptor–mediated lipolysis in the intra-abdominal fat of these subjects. Despite these genetic differences in loss of intra-abdominal adipose tissue, improvement in glucose disposal was similar between groups. ACKNOWLEDGMENTS
This study was supported in part by National Institutes of Health Grants R01-DK52752 to E.T.P.; RR-00109, a National Research Service Award, to R.D.S. (AG-05791); a Research Fellowship from the American Heart Association to A.T.; a Brookdale National Fellowship to J.D.W.; and a Clinical Associate Physician Award (3-M01-RR2719–11S3) and the Paul Beeson Physician Faculty Award from the American Federation of Aging Research to A.R.S. DIABETES, VOL. 49, OCTOBER 2000
A. TCHERNOF AND ASSOCIATES
We thank the staff of the General Clinical Research Center at the University of Vermont for their cooperation. We also acknowledge the work of Denise DeFalco-McGeein, RN, NPC, for the clinical management of volunteers and Demian Lewis for his expert technical assistance. REFERENCES 1. Walston J, Silver K, Bogardus C, Knowler WC, Celi FS, Austin S, Manning B, Strosberg AD, Stern MP, Raben N, Sorkin JD, Roth J, Shuldiner AR: Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the 3-adrenergic-receptor gene. N Engl J Med 333:343–347, 1990 2. Sakane N, Yoshida T, Umekawa T, Kogure A, Takakura Y, Kondo M: Effects of Trp64Arg mutation in the 3-adrenergic receptor gene on weight loss, body fat distribution, glycemic control, and insulin resistance in obese type 2 diabetic patients. Diabetes Care 20:1887–1890, 1997 3. Sipiläinen R, Uusitupa M, Heikkinen S, Rissanen A, Laakso M: Polymorphism of the 3-adrenergic receptor gene affects basal metabolic rate in obese Finns. Diabetes 46:77–80, 1997 4. Yoshida T, Sakane N, Umekawa T, Sakai M, Takahashi T, Kondo M: Mutation of 3-adrenergic-receptor gene and response to treatment of obesity. Lancet 346:1433–1434, 1995 5. Sakane N, Yoshida T, Umekawa T, Kondo M, Sakai Y, Takahashi T: 3-adrenergic-receptor polymorphism: a genetic marker for visceral fat obesity and the insulin resistance syndrome. Diabetologia 40:200–204, 1997 6. Garcìa-Rubi E, Starling RD, Tchernof A, Matthews DE, Walston JD, Shuldiner AR, Silver AJ, Poehlman ET, Calles-Escandon J: Trp64Arg variant of the 3-adrenoceptor and insulin resistance in obese postmenopausal women. J Clin Endocrinol Metab 83:4002–4005, 1998 7. Allison DB, Heo M, Faith MS, Pietrobelli A: Meta-analysis of the association of the Trp64Arg polymorphism in the 3 adrenergic receptor with body mass index. Int J Obes 22:559–566, 1998 8. Urhammer SA, Clausen JO, Hansen T, Pedersen O: Insulin sensitivity and body weight changes in young white carriers of the codon 64 amino acid polymorphism of the 3-adrenergic receptor gene. Diabetes 45:1115–1120, 1998 9. Rissanen J, Kuopusjärvi M, Pihlajamäki J, Sipiläinen R, Heikkinen S, Vanhala M, Kekäläinen P, Kuusisto J, Laakso M: The Trp64Arg polymorphism of the 3-adrenergic receptor gene: lack of association with NIDDM and features of insulin resistance syndrome. Diabetes Care 20:1319–1323, 1997 10. Moriarty M, Wing RR, Kuller LH, Ferrell RE: Trp64Arg substitution in the 3-adrenergic receptor does not relate to body weight in healthy, premenopausal women. Int J Obes 21:826–829, 1997 11. Tchernof A, Starling RD, Walston JD, Shuldiner AR, Dvorak RV, Silver K, Matthews DE, Poehlman ET: Obesity-related phenotypes and the 3-adrenoceptor gene variant in postmenopausal women. Diabetes 48:1425–1428, 1999 12. Lönnqvist F, Thöme A, Nilsell K, Hoffstedt J, Arner P: A pathogenic role of visceral fat beta 3-adrenoceptor in obesity. J Clin Invest 95:1109–1116, 1995 13. Kim-Motoyama H, Yasuda K, Yamaguchi T, Yamada N, Katakura T, Shuldiner
DIABETES, VOL. 49, OCTOBER 2000
AR, Akanuma Y, Ohashi Y, Yazaki Y, Kadowaki T: A mutation of the 3-adrenergic receptor is associated with visceral obesity but decreased serum triglyceride. Diabetologia 40:469–472, 1997 14. Umekawa T, Yoshida T, Sakane N, Kogure A, Kondo M, Honjyo H: Trp64Arg mutation of 3-adrenoceptor gene deteriorates lipolysis induced by 3-adrenoceptor agonist in human omental adipocytes. Diabetes 48:117–120, 1999 15. Li LS, Lönnqvist F, Luthman H, Arner P: Phenotypic characterization of the Trp64Arg polymorphism in the beta3-adrenergic receptor gene in normal weight and obese subjects. Diabetologia 39:857–860, 1996 16. Hoffstedt J, Poirier O, Thörne A, Lönnqvist F, Herrman SM, Cambien F, Arner P: Polymorphism of the human 3-adrenoceptor gene forms a well-conserved haplotype that is associated with moderate obesity and altered receptor function. Diabetes 48:203–205, 1999 17. Widen E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC: Association of a polymorphism in the 3-adrenergic receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 333:348–351, 1995 18. Taylor HL, Jacobs DR, Schucker B, Knudsen J, Leon AS, Debacker G: A questionnaire for the assessment of leisure time physical activities. J Chronic Dis 31:741–755, 1978 19. Spayd RW, Bruschi B, Burdick BA, Dappen GM, Eikenberry JN, Esders TW, Figueras J, Goodhue CT, LaRossa DD, Nelson RW, Rand RN, Wu TW: Multilayer film elements for clinical analysis: applications to representative chemical determination. Clin Chem 24:1348–1350, 1978 20. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC: Enzymatic determination of total serum cholesterol. Clin Chem 20:470–475, 1974 21. Finley PR, Shifman RB, Williams RJ, Lichti DA: Cholesterol in high-density lipoproteins: use of Mg2+ dextran sulfate in its enzymatic measurement. Clin Chem 24:931–933, 1978 22. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 18:499–502, 1972 23. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223, 1979 24. Fogelholm M, Valve R, Kukkonen-Harjula K, Nenonen A, Hakkarainen V, Laakso M, Uusitupa M: Additive effects of the mutations in the 3-adrenergic receptor and uncoupling protein-1 genes on weight loss and weight maintenance in Finnish women. J Clin Endocrinol Metab 83:4246–4250, 1998 25. Kissebah AH, Peiris AN: Biology of regional body fat distribution: relationship to non-insulin-dependent diabetes mellitus. Diabet Metab Rev 5:83–109, 1989 26. Després JP, Marette A: Relation of components of insulin resistance syndrome to coronary disease risk. Curr Opin Lipidol 5:274–289, 1994 27. Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL: Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 48:839–847, 1999 28. Després JP, Lamarche B: Effects of diet and physical activity on adiposity and body fat distribution: implications for the prevention of cardiovascular disease. Nutr Res Rev 6:137–159, 1993
1713
